Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Gunna Drinks is a company that manufactures and sells craft soft drinks, consisting of natural juices with less than 5% sugar and no artificial colours or flavours. They have outshone established competitors like Gingerella, Fentimans & FeverTree in taste tests, and its recipes draw inspiration from around the world. Gunna is stocked in major supermarkets and convenience stores across the UK such as Co-op, Sainsbury’s, Amazon, Ocado, and JD Wetherspoon. Gunna Drinks has experienced 85% revenue growth in 2019 and was overfunded by 78% in its last crowdfunding round. The company will utilise the investment to boost consumer marketing to drive rapid revenue growth and develop new products and flavours.
days to go:
Expired
investment:
£274,880
Hansine is a luxury resort wear brand designed with strong ethical values and produced in London to the booming global market sector. The product's initial launch has proved its global demand with retailers like Liberty and Neiman Marcus. Hansine aims at becoming a definitive luxury destination wear brand. This brand has been worn by the topmost global influencers, and it has been featured by high-profile media platforms such as FT, Elle, Grazia, and The Telegraph. With the proceeds, the company will invest in production, facilitate the third phase of the business plan, staffing and marketing.
days to go:
Expired
investment:
£56,820
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go:
Expired
investment:
£2,160,000
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
LuxDeco aims to connect luxury shoppers around the globe to the world's finest interior brands through personal shopping technology, white-label e-commerce service and a curated online marketplace. It believes that its proprietary algorithms, data science, and expert curators who aggregate and standardise product data from hundreds of partners, set it apart from traditional e-commerce and present the most relevant selection to the users. LuxDeco offers a curated selection of products from 350+ premium brands with minimum inventory risk while providing a personalised shopping experience. Moreover, leading interior brands like Ralph Lauren and Aerin have also joined the platform. Till date, with £920 average order, it has seen £13m+ gross sales. In Y/E March 2019, it achieved £546k gross profit after fulfilment (-£1.59m P+L).
days to go:
Expired
investment:
£1,518,730
